{"id":12897,"date":"2026-04-27T17:43:48","date_gmt":"2026-04-27T15:43:48","guid":{"rendered":"https:\/\/event.businessfrance.fr\/next-healthcare-north-america\/?p=12897"},"modified":"2026-05-06T23:25:52","modified_gmt":"2026-05-06T21:25:52","slug":"biper-therapeutics","status":"publish","type":"post","link":"https:\/\/event.businessfrance.fr\/next-healthcare-north-america\/biper-therapeutics\/","title":{"rendered":"BiPER Therapeutics"},"content":{"rendered":"\n
\"\"<\/div><\/div>
<\/div><\/div>
\n

BiPER Therapeutics<\/h1><\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>
<\/div><\/div>
\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n

Biotech, Pharma<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

Series A – $5M raised<\/p>\n\n\n\n

Initiated $35M fund raising<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

Founded in 2021<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

11-20 employees<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n\n\n

France 2030 Laureate<\/p>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n

<\/div>
<\/div><\/div>
\n
\n
\n

First-in-class selective BiP inhibitors to treat cancers and beyond<\/mark><\/mark><\/strong><\/h3><\/div>\n\n\n\n
\n
oncology<\/a><\/div>\n\n\n\n
immunology<\/a><\/div>\n<\/div>\n\n\n\n

BiPER Therapeutics opens a new therapeutic pathway in the treatment of cancers and immunological disorders. BiPER Therapeutics develops first-in-class selective BiP inhibitors as targeted therapy with a first focus on treating cancer patients with BPR001-615 a first-in-class selective BiP inhibitor at 6 months for first-in-patient clinical trials.<\/mark><\/p>\n\n\n\n

BiPER Therapeutics’ first clinical candidate BPR001-615 is a first-in-class oral small molecule to treat gastro-intestinal tumors by pushing cancer cells to burn out. BPR001-615 inhibits BiP, a key protein involved in cancer cell survival and associated with very poor prognosis of patients when overexpressed in tumors and in plasma of patients. BPR001-615 has been developed to treat the 50% of patients with high BiP expression through a precision medicine approach based on overexpression level of BiP in plasma of patients. BPR001-615 has been developed as an oral drug in monotherapy or in combination with standard of care to improve patient outcomes. In preclinical studies, patent-protected data demonstrate that BPR001-615 is effective in monotherapy outperforming standard of care and enhances a wide range of standard of care agents like chemotherapies, targeted therapies and immunotherapies. Very good tolerability profile of BPR001-615 has been confirmed by toxicology studies in rats and dogs with a confirmed high NOAEL and a therapeutic index of 10 in vivo.<\/mark><\/p>\n<\/div>\n\n\n\n

<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>
<\/div><\/div>
\n
\n
\n

CONTACT INFORMATION<\/mark><\/strong><\/h3><\/div>\n\n\n\n

Mehdi<\/strong> Chelbi<\/strong><\/strong><\/strong><\/strong><\/strong><\/strong><\/p>\n\n\n\n